A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2016
Price : $35 *
At a glance
- Drugs Ribociclib (Primary) ; Letrozole
- Indications Breast cancer
- Focus Pharmacodynamics
- Acronyms MONALEESA-1
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 18 Aug 2016 This trial has been completed in France as per European Clinical Trials Database record.
- 31 Dec 2015 Status changed from completed to discontinued, according to ClinicalTrials.gov record.